Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Carcinoma × Ramucirumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 18 Stomach Neoplasms 17 Neoplasms 8 Colorectal Neoplasms 7 Neoplasm Metastasis 6 Carcinoma, Hepatocellular 6 Adenocarcinoma 6 Esophageal Neoplasms 5 Carcinoma, Renal Cell 5 Breast Neoplasms 5 Colonic Neoplasms 4 Urinary Bladder Neoplasms 3 Urethral Neoplasms 3 Melanoma 3 Liver Neoplasms 3 Biliary Tract Neoplasms 3 Ureteral Neoplasms 2 Solid Tumors 2 Sarcoma 2 Rectal Neoplasms 2 Ovarian Neoplasms 2 Non-small Cell Lung Cancer Metastatic 2 Malignant Solid Tumor 2 Lung Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Transitional Cell 2 Solid Cancer 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1

Interventions

Carboplatin 28 pembrolizumab 21 Paclitaxel 20 Cisplatin 20 Pemetrexed 17 Gemcitabine 10 durvalumab 9 Nivolumab 9 osimertinib 8 130-nm albumin-bound paclitaxel 8 Everolimus 7 Docetaxel 7 Sunitinib 6 Sorafenib 6 Fluorouracil 5 Cetuximab 5 Axitinib 5 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 5 volociximab 4 trebananib 4 cabozantinib 4 atezolizumab 4 Radiotherapy 4 reolysin 3 liposomal doxorubicin 3 lenvatinib 3 epothilone B 3 catumaxomab 3 brigatinib 3 Trastuzumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04151563 2023-12-19

CheckMate 79X

Bristol-Myers Squibb

Phase 1/2 Withdrawn

Carcinoma, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡